Options covered in this guide
CJC-1295 / Ipamorelin
This formulation pairs CJC-1295 and Ipamorelin, two peptides studied in growth-hormone signaling research.
Formulation & presentation
CJC-1295 6 mg + Ipamorelin 12 mg.
Confirm the CJC-1295 variant, including DAC status, and the container volume before comparing formulations.
Sermorelin
Sermorelin is an analog of growth-hormone-releasing hormone, studied in growth-hormone signaling.
Formulation & presentation
Sermorelin, 10 mg total, in a 5 mL presentation.
Sermorelin is distinct from Tesamorelin and from the CJC-1295 / Ipamorelin blend.
Tesamorelin
Tesamorelin is a synthetic growth-hormone-releasing hormone analog. This presentation contains 10 mg.
Formulation & presentation
Tesamorelin, 10 mg total.
An approved medicine containing a compound, where applicable, does not establish approval of every preparation bearing that compound’s name. The exact manufacturer and product must be identified.
CJC-1295
CJC-1295 is discussed in growth-hormone signaling research. This standalone profile is separate from the CJC-1295 / Ipamorelin blend.
Formulation & presentation
Standalone strength and container volume require confirmation.
Standalone formulation, strength, volume, DAC status and availability require confirmation.
Ipamorelin
Ipamorelin is discussed in growth-hormone signaling research. This standalone profile is separate from the CJC-1295 / Ipamorelin blend.
Formulation & presentation
Standalone strength and container volume require confirmation.
Standalone formulation, strength, volume and availability require confirmation.
Understanding the formulation
For CJC-1295 / Ipamorelin, review the active compound or compounds, concentration, presentation and proposed purpose. A blend name does not establish that every ingredient has the same evidence or clinical role. Ask the clinician to distinguish research findings from established uses and explain the evidence relevant to your particular goal.
What to review in your consultation
Your discussion of CJC-1295 / Ipamorelin should connect the profile information above to your individual health history. Bring your medication and supplement list, allergies, previous treatment experience and any current symptoms. Ask what evaluation or testing is needed and whether another approach would better address your concern.
Making an informed decision
Review the exact product, its regulatory status and the evidence for the intended use. Concentration and container size describe a presentation; they are not a personal dosing plan. The clinician explains potential adverse effects, relevant interactions and limitations before any treatment decision. An investigational profile is not a recommendation or an offer of an approved treatment.
Monitoring & next steps
If an appropriate treatment is agreed, the plan should describe how progress and tolerability will be reviewed, when follow-up takes place and whom to contact with concerns. Discuss realistic expectations and how decisions about continuing or changing the plan will be made. Personal medical guidance comes from the clinician who assesses you, rather than from a product description.
Educational information. Individual suitability and medical decisions require a consultation with a qualified clinician.
